Introduction: The 2026 Congress of the European Society for Medical Oncology (ESMO) was held in Madrid, Spain, from October 23 to 27. At this premier global oncology event, the OptiTROP-Lung06 study, led by Professor Caicun Zhou of Shanghai East Hospital, presented its findings in a major oral presentation, with simultaneous publication in the New England Journal of Medicine (NEJM). This Phase III study provided the first head-to-head evidence that the TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) plus pembrolizumab was superior to the standard regimen of platinum-based doublet chemotherapy plus pembrolizumab as first-line treatment for patients with driver gene-negative, PD-L1-negative (expression <1%) nonsquamous non-small cell lung cancer (NSCLC).

Greater Survival Benefit

At a median follow-up of 9.7 months, progression-free survival (PFS) assessed by blinded independent central review (BICR) was significantly longer in the sac-TMT plus pembrolizumab group than in the chemotherapy plus pembrolizumab group (15.0 vs. 5.7 months; HR, 0.49; 95% CI, 0.36–0.65; P<0.0001) [1]. Median PFS was three times that of the control group, surpassing the current standard-of-care (SOC) regimen of PD-(L)1 inhibitor plus chemotherapy.

Better Response Outcomes

Both median duration of response (DoR) and the 12-month DoR rate doubled. Median DoR was 13.6 versus 6.8 months (HR, 0.47; 95% CI, 0.29–0.77), while the 12-month DoR rate was 61.7% versus 27.2%.

Improved Safety Profile

The rates of grade ≥3 treatment-emergent adverse events (TEAEs) and treatment discontinuation were both lower in the sac-TMT plus pembrolizumab group. Grade ≥3 TEAEs occurred in 47.6% versus 60.6% of patients, while treatment discontinuation rates were 5.7% versus 14.2%, respectively.

On this occasion, Oncology Frontier invited several leading international lung cancer experts to discuss this landmark study: Professor Solange Peters from Lausanne University Hospital, Switzerland; Professor Tetsuya Mitsudomi from Izumi Municipal General Hospital, Japan; Professor Benjamin P. Levy from Johns Hopkins University, USA; Professor Byoung Chul Cho from Yonsei Cancer Center, South Korea; Professor Jacob Sands from Dana-Farber Cancer Institute, USA; Dr. Michael Davidson from The Royal Marsden Hospital, UK; Professor Suresh Senan from Amsterdam University Medical Centers, the Netherlands; and Professor Xiuning Le from The University of Texas MD Anderson Cancer Center, USA. They explored the potentially transformative impact of the ADC plus immunotherapy approach on the first-line treatment landscape for advanced NSCLC.


Oncology Frontier: OptiTROP-Lung06 is the first global Phase III study to demonstrate that a TROP2 ADC combined with immunotherapy is superior head-to-head to immunotherapy plus chemotherapy in first-line treatment of driver gene-negative, PD-L1-negative nonsquamous NSCLC. What does the improvement in PFS (15.0 vs. 5.7 months; HR, 0.49) mean for clinical practice?

Professor Solange Peters
Lausanne University Hospital, Switzerland

Even after the KEYNOTE-189 study, patients with PD-L1-negative disease remain a population with substantial unmet needs, deriving very limited benefit from immunotherapy. The combination of sac-TMT and immunotherapy has demonstrated remarkable efficacy in patients with PD-L1-negative disease. The hazard ratios for both OS and PFS are close to 0.5, meaning that the likelihood of controlling disease and maintaining survival may be doubled. These data are extremely encouraging. The regimen also has excellent tolerability and is convenient to administer, while the magnitude of benefit is truly outstanding. I have complete confidence in data from China. If I could prescribe this treatment tomorrow, I would immediately revise my treatment guidelines.

Professor Tetsuya Mitsudomi
Izumi Municipal General Hospital, Japan

For patients without driver gene mutations and with no PD-L1 expression, the global standard of care is based on platinum-based chemotherapy combined with pembrolizumab, as established by the KEYNOTE-189 study. OptiTROP-Lung06 demonstrated that sac-TMT plus pembrolizumab was significantly superior to pembrolizumab plus chemotherapy, with sac-TMT replacing platinum-based doublet chemotherapy. PFS was significantly improved, with a strong indication of an OS benefit.

Clearly, this regimen outperformed the current standard of care. I believe it has the potential to become a future standard treatment and may change clinical practice. The trial enrolled patients exclusively in China, and sac-TMT has not yet been approved in Japan. However, if global trials also demonstrate the benefits of replacing chemotherapy with sac-TMT, this approach could become the next standard of care. At present, it is one of the most promising strategies for patients with driver gene-negative, PD-L1-negative NSCLC.

Dr. Michael Davidson
The Royal Marsden Hospital, UK

OptiTROP-Lung06 clearly demonstrated clinically meaningful PFS and OS benefits in patients with PD-L1-negative, driver gene-negative NSCLC. The regimen also had a manageable safety profile, which was even more favorable than that of the current standard chemotherapy plus immunotherapy, clearly demonstrating a synergistic effect with pembrolizumab. I believe this significantly expands the therapeutic landscape of ADCs.

Professor Suresh Senan
Amsterdam University Medical Centers, the Netherlands

This trial offers us a clear opportunity to move toward treatments that are more effective, more patient-friendly, and less toxic. Prolonging PFS is a highly meaningful endpoint for clinicians, patients, and their caregivers alike. If this goal can be achieved with lower toxicity than conventional treatment, the new regimen will replace the standard of care. It gives patients and clinicians an opportunity to move away from traditional chemotherapy-based combinations. This represents a major change in clinical practice, and I believe it would be an extremely beneficial change for patients.

Professor Benjamin P. Levy
Johns Hopkins University, USA

We are accumulating more experience in toxicity management and exploring potential biomarkers in greater depth. I am very excited about the prospect of ADCs establishing a firm position in first-line treatment. I encourage everyone to follow these developments closely.

Professor Byoung Chul Cho
Yonsei Cancer Center, South Korea

In the near future, we will have an increasing number of highly effective and well-tolerated ADCs. These agents will be combined with current standard treatments to improve outcomes for patients with lung cancer in both the first-line and later-line settings.


Oncology Frontier: Safety and tolerability often determine whether an ADC plus immunotherapy regimen can truly be used in the first-line setting. In this study, grade ≥3 adverse events occurred in 47.6% of patients in the ADC group, and the treatment discontinuation rate was relatively low (5.7%). However, the incidence of oral mucositis was approximately 51%. How do you interpret these safety data? How manageable do you think this regimen will be in real-world practice?

Professor Solange Peters
Lausanne University Hospital, Switzerland

These trials remind us that, to adopt a regimen with greater toxicity, we need to see a substantial magnitude of benefit—and we have indeed seen a major benefit in patients with PD-L1-negative disease. We need to learn more about managing adverse effects, including treatment interruptions, dose adjustments or modifications, and perhaps preventive measures for problems such as oral mucositis. In clinical practice, oral mucositis is manageable, and the magnitude of benefit is sufficient to outweigh its impact on toxicity.

Professor Benjamin P. Levy
Johns Hopkins University, USA

The safety data we are seeing today are actually quite encouraging. The treatment group experienced even fewer treatment-related adverse events than the control group. Oral mucositis occurred in more than half of the patients, but most cases were grade 1 or 2. This is a known adverse effect of TROP2 ADCs, and we are already quite familiar with how to manage it. As we gain more experience, we will become better at handling it through proactive preventive strategies, such as using dexamethasone mouth rinses and sucking on ice chips during infusions. I am not only encouraged by the efficacy results but also quite reassured by the safety profile.

Professor Suresh Senan
Amsterdam University Medical Centers, the Netherlands

In this study population, only 5.7% of patients discontinued treatment because of treatment-related adverse events. The discontinuation rate in the sac-TMT group was substantially lower than that in the standard-treatment group. The fact that stomatitis and ocular toxicity occurred without treatment interruption suggests that clinicians managed these events effectively. In oncology, we are accustomed to managing unusual toxicities, and what is needed is a monitoring system that provides adequate support for patients. However, we may need to pay particular attention when treating non-Chinese populations and older patients.

Professor Tetsuya Mitsudomi
Izumi Municipal General Hospital, Japan

Oral mucositis is generally not life-threatening, but patients still have to endure the associated pain. Its high incidence is a concern, although we may be able to develop preventive or therapeutic measures to address it. We have seen a similar process with amivantamab in the MARIPOSA study. When amivantamab was first introduced, it was associated with severe skin toxicity and venous thrombosis. Subsequently, many preventive and therapeutic strategies were developed. Sac-TMT may also benefit from improved treatment and prevention strategies. Reducing the incidence of adverse effects will be a very important next step.

Professor Jacob Sands
Dana-Farber Cancer Institute, USA

Oral mucositis deserves particular attention. These events are largely related to TROP2 targeting: any ADC that effectively targets TROP2 while carrying a chemotherapy payload would be expected to produce such reactions. We also observed cytopenias, some degree of nausea, and fatigue. However, this toxicity profile is by no means prohibitive for clinical use. There are certainly aspects that clinicians need to understand and manage appropriately.

Conclusion

With an impressive PFS result (HR, 0.49), OptiTROP-Lung06 has opened up a new avenue in the field of PD-L1-negative NSCLC, often characterized as an “immunologically cold” tumor, bringing renewed hope to patients who have long had limited effective treatment options.

International experts broadly agree that the ADC plus immunotherapy approach has the potential to reshape the first-line treatment landscape. However, global validation, stratification by co-mutations, exploration of TROP2 biomarkers, and more refined management of toxicities such as oral mucositis remain key questions that must be addressed before this approach can become a global standard of care.

With the success of OptiTROP-Lung05 and OptiTROP-Lung06, China-originated ADCs are moving from “following” to “leading” in the field. The vision of “From China, for the World” is increasingly taking shape in lung cancer treatment.